Rx Drug Prices Up 2.2% In 3rd Qtr

29 October 1997

Prescription drug prices rose 2.2% in third-quarter 1997, against 2.3%in the like 1996 quarter and 3.6% in third-quarter 1995, says First DataBank's quarterly drug price report. All major categories had minimal changes and most seemed to vary independently of each other, but each basically followed its own five-year, third-quarter trend, it says.

Single-source products were up 2.7%, the same average rise as in 1995; the 1996 rise was 2.6%. Their average price rises have changed little in the last five years, the report said. Multiple-source products rose 2.1% against 2.3% in 1996 and 3.8% in 1995, a record third-quarter low for the past five years. Branded products' prices rose 3.2%, against 2.6% in third-quarter 1996, and multiple-source generics were up 1.8%, compared with 2.2% in 1996.

Products from the top 25 drug firms had the highest average rise of all categories analyzed, up to 3.9% from 3.6% in 1996.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight